Vamifeport hydrochloride is under clinical development by Vifor Pharma Management and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase II drugs for Sickle Cell Disease have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vamifeport hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vamifeport hydrochloride overview
Vamifeport (VIT-2763) is under development for the treatment of haemochromatosis, beta thalassemia. It is administered through oral route. The drug candidate acts by targeting ferroportin.
Vamifeport was under development for the treatment of sickle cell disease.
Vifor Pharma Management overview
Vifor Pharma Management (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines for unmet medical needs of the gastrointestinal tract. It operates production plants in Portugal and Switzerland, and carries out business through subsidiaries. Vifor Pharma is headquartered in St. Gallen, Switzerland.
For a complete picture of Vamifeport hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.